Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Shire buying Conejo Valley’s Baxalta
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen teams up with Merck on melanoma treatments
Thousand Oaks-based Amgen and pharmaceutical giant Merck are working together to evaluate the safety and effectiveness of combined treatments for melanoma patients.
Amgen reports positive trial results for high-cholesterol treatment
The portion of Amgen’s Phase 3 trial of evolocumab that evaluated patients with high cholesterol who cannot tolerate statins has met goals related to percent reduction of low-density lipoprotein cholesterol.
Amgen to buy KAI for $315M
Amgen said April 10 that it plans to buy San Francisco-based KAI Pharmaceuticals for $315 million in cash in a deal that would give it worldwide rights to an experimental treatment for patients with chronic kidney disease. Thousand Oaks-based Amgen said the deal would give it worldwide rights, excluding in Japan, to KAI’s lead product, Read More →
